MRNA May 2024 105.000 call
| Previous close | 36.66 |
| Open | 36.67 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 105.00 |
| Expiry date | 2024-05-24 |
| Day's range | 36.66 - 36.67 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
BenzingaStocks, Gold Reach New Record Highs, Cruise Stocks Rally, GameStop Sinks: What's Driving Markets Monday?
Wall Street kicked off the new week on a high note, with all major U.S. indices posting gains and reaching fresh record highs by midday trading in New York, as the bull market momentum remains strong. The S&P 500 index surged to 5,325 points during the session, matching last Thursday’s all-time high. The tech-heavy Nasdaq 100 climbed past 18,670 points, setting new record highs. The Dow Jones remained steady at 40,000, its highest level ever. The rally in metal commodities continued, with gold,
Barrons.comModerna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
BenzingaEuropean Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte
